The Latest Cardiac and Vascular News
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive…
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company’s strategy to address coronary and peripheral disease MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today…
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced…
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire…
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and…
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid…
MARLBOROUGH, Mass., Aug. 27, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology in the company’s structural heart portfolio….
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial…
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
